Silexion Therapeutics (NASDAQ:SLXN) (NASDAQ:SLXN) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of targeted therapies for oncology and immunological diseases. Founded in 2015 as a spin-off from leading academic research institutions, the company has its headquarters in Cambridge, Massachusetts, with additional research facilities in the San Francisco Bay Area and a European offices in Basel, Switzerland.
The company’s core expertise lies in its proprietary small-molecule and biologics platform, which enables the design of highly selective inhibitors and immune-modulating agents. Silexion’s flagship program, SLX-101, is a novel kinase inhibitor currently in Phase I clinical trials for the treatment of advanced solid tumors, while SLX-201, an experimental monoclonal antibody targeting pro-inflammatory cytokines, has entered preclinical development for autoimmune disorders such as rheumatoid arthritis and inflammatory bowel disease.
Silexion maintains collaborative partnerships with leading academic centers, including Dana-Farber Cancer Institute and Institut Pasteur, to advance its preclinical pipeline and access cutting-edge translational research capabilities. The company’s drug-manufacturing processes are supported by a strategic alliance with a Swiss contract development and manufacturing organization (CDMO), ensuring scalable production and adherence to global regulatory standards.
Under the leadership of CEO Dr. Amanda Liu, a veteran of the biopharma industry with over two decades of drug development experience, and CFO Mark Bennett, Silexion is focused on executing its clinical milestones and expanding its research footprint. Guided by an experienced board of directors and a multidisciplinary scientific advisory council, the company aims to address unmet medical needs and deliver precision therapeutics to patients worldwide.
